Skip to content
Delayed ~15 min

SI SHOULDER INNOVATIONS

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: not announced yet

What 8 analyst firms say about SHOULDER INNOVATIONS: their latest ratings, price targets and how far the stock is from them. How it works

20.54 USD+0.17 (+0.83%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+24.1%to the avg target 25.50 USD+4.96 USD
Buy 6 · Hold 1 · Sell 0

7 rated views · 8 analyst/firm records · 8 firms

Latest report12 Oct 2026avg report date 24 Jun
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8070
  • Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8069

Recent analyst activity · last 90 days

Our tracked history has 3 reports on SI from 3 analyst firms in the last 90 days (8 firms in the past year).

Comparing each firm's latest target with its previous one: 1 raised its price target and 1 has its first observed target in the past year.

No firm's latest available rating differs from its previous one.

Latest observed target change: BTIG Research raised its target from $24.00 (set 11 Mar 2026) to $27.00 on 12 Oct 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
BTIGRyan ZimmermanBuy12 Oct 202627.00 USD
Goldman SachsDavid H RomanBuy14 May 202624.00 USD
JefferiesMatthew C TaylorBuy7 Aug 202626.00 USD
Morgan StanleyManan GosaliaBuy2 Dec 202523.00 USD
Piper SandlerMatt O'BrienBuy7 Aug 202625.00 USD
UBSPatrick WoodBuy10 Aug 202628.00 USD
Weiss RatingsUnnamed analyst—30 Oct 2026—
Data feed RESEARCHResearch TeamHold15 Jun 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 06:55 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.